Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018)

Kim Y. H.; Bagot M.; Pinter-Brown L.

首页> 外文期刊>The lancet oncology >Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018)

【24h】

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018)

机译：Mogamulizumab与vorinostat在先前治疗的皮肤T细胞淋巴瘤（Mainahic）：国际，开放标签，随机，受控第3阶段试验（Vol 19，PG 1192,2018）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第11期|共1页
作者
Kim Y. H.; Bagot M.; Pinter-Brown L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018) [J] . Kim Y. H., Bagot M., Pinter-Brown L. The lancet oncology . 2018,第11期

机译：Mogamulizumab与vorinostat在先前治疗的皮肤T细胞淋巴瘤（Mainahic）：国际，开放标签，随机，受控第3阶段试验（Vol 19，PG 1192,2018）
2. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial (vol 19, pg 295, 2018) [J] . de Boer S. M., Powell M. E., Mileshkin L. The lancet oncology . 2018,第4期

机译：佐剂化学疗法与放射疗法单独用于高危子宫内膜癌的妇女（Portec-3）：国际，开放标签，多期中心，随机，第3阶段试验的最终结果（Vol 19，PG 295,2018）
3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (vol 391, pg 748, 2018) [J] . Powles T., Duran I, van der Heijden M. The Lancet . 2018,第10156期

机译：紫红素与化疗在铂治疗的局部晚期或转移性尿路上皮癌（IMVigor211）中：多期，开放标签，第3阶段随机对照试验（Vol 391，PG 748,2018）
4. Accelerated versus standard epirubicin followed by cyclophosphamide methotrexate and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre phase 3 open-label randomised controlled trial [O] . David Cameron, James P Morden, Peter Canney, -1

机译：英国TACT2随机试验（CRUK / 05/19）：加速与标准表柔比星联合环磷酰胺甲氨蝶呤氟尿嘧啶或卡培他滨作为乳腺癌的辅助治疗：一项多中心3期开放标签随机对照试验
5. PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTAT [O] . S. Hudgens, L. Floden, M. Leoni, 2018

机译：PCN350 - 用摩仙素酸或Vorinostat治疗皮肤T细胞淋巴瘤患者Skindex-29上的疾病特异性皮肤症状项目的评估

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018)

著录项

相似文献

相关主题

期刊订阅